Panthera’s UK oncology clinical trial sites open for studies
- More than 1000 International Cancer Trials Suspended Due to COVID-19 https://www.cancerresearch.org/scientists/immuno-oncology-landscape/covid-19-oncology-clinical-trials
- Panthera working with the state of the art Rutherford Cancer Centres across the UK is open for clinical research activities including screening
Over a thousand oncology clinical trials have been suspended due to Covid putting back research which is vital for patients across the world. The Rutherford Cancer Centres which are spread across the UK have the space and capacity to run oncology trials having put in place measures to meet and even exceed the guidelines laid down by the regulatory agencies.
Professor Karol Sikora Medical Director of Rutherford explained “Our state of the art cancer centres have the capacity to safely undertake clinical trial activity including screening. We have implemented a very strict safety methodology covering all patients and staff which meet all the official guidelines.”
Stuart Young CEO of Panthera commented “Even before Covid there was a grave shortage of top tier oncology trial sites. Today there is a huge backlog which will in most cases continue until at least the end of the year as hospitals catch up with cancelled procedures. We through our partnership with Rutherford not only have capacity now but also have the experienced PIs across more than 40 cancer types to undertake both phase 2 and 3 trials.”
Rutherford’s independent network currently consists of four cancer treatment centres in Newport, Wales, Reading by London, Bedlington in the North West of the UK and Liverpool and draw patients from all over the UK offering pharma and CROs access to patients through more than 170 referring oncologists.
Each of the Rutherford Cancer Centres has state-of-the-art diagnostics including MRI, CT, and proton beam therapy as well as offering chemotherapy, immunotherapy and radiotherapy treatments. These facilities combined with leading oncologists, Panthera’s clinical trial professionals and an experienced cancer care team ensure that patients will receive the highest possible standard of care.
Panthera has a network of seven clinical trial sites in the UK with several more in development. These include sites where specialist trials for oncology, vaccines and neurology can be carried out by experienced GCP trained staff. Panthera also undertakes research in conditions usually treated in primary care including cardiac disease, osteoarthritis, osteoporosis, diabetes, allergies and migraine.
Due to its geographic spread and links into the local and national medical community Panthera has access to a patient pool of millions of patients.
About Panthera Biopartners – an Independent Site Management Organisation
Panthera Biopartners was founded by Dr Ian Smith – founder of Synexus - and Professor John Lyon – previously senior executive in Covance and serial entrepreneur - to provide CROs and pharma clients with services relating to the recruitment and running of clinical trials at customised clinical trial sites by GCP trained healthcare professionals.
Panthera has a growing network of sites across the UK managing studies in a variety of conditions in both primary care settings and hospital sites running trials in key secondary care conditions such as CNS, oncology and NASH with specialist investigators.
About Rutherford Health
Rutherford Health plc Rutherford Health plc is the UK incorporated holding company of a group committed to providing innovative cancer care of the highest quality. The Group's oncology centres in the UK, named The Rutherford Cancer Centres, offer a comprehensive range of cancer treatments to patients including proton beam therapy (“PBT”), conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services. The company was founded in 2015 by Mike Moran and UK and international cancer experts, including Professor Karol Sikora, former head of the World Health Organisation’s cancer programme.
The Rutherford Cancer Centres feature the most advanced technologies and Rutherford Health Plc has formed a partnership with IBA (Ion Beam Applications), the world’s leading provider of proton beam therapy solutions and Philips, a leader in health technology.
All centres offer proton beam therapy to medically-insured private patients, self-paying patients and NHS patients where the Rutherford is commissioned to provide these services.
For more information on the Rutherford Cancer Centres, please visit: http://www.therutherford.com